Sustained effectiveness, safety and therapeutic drug monitoring of tioguanine in a cohort of 274 IBD patients intolerant for conventional therapies.
Melek SimsekDebbie S DebenCarmen S HorjusMelanie V BénardBirgit I Lissenberg-WitteHans J C BuiterMatthijs van LuinMargien L SeinenChris J J MulderDennis R WongNanne K H de BoerAdriaan A van BodegravenPublished in: Alimentary pharmacology & therapeutics (2019)
Long-term tioguanine therapy for at least 12 months was effective in 51% and well tolerated as a maintenance treatment for IBD in about 70% of patients. Adverse events were common, but mainly mild or moderate. 6-Thioguanine nucleotide threshold concentration ≥ 700 pmol/8×108 RBC is proposed as target level with higher odds for clinical effectiveness.